Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of NK012 in patients with multiple myeloma
jRCT2080221611Phase 2
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Oct 2011
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NK012 in multiple myeloma (MM), sponsored by Nippon Kayaku Co., Ltd.
02
Drugs
NK012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080221611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221611.